Radiation plus immunotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (AK104) for people with esophageal squamous cell cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have esophageal squamous cell cancer that has returned or spread, and you have not had PD-1/PD-L1 immunotherapy before.
- You have at least two measurable tumors, one of which can be treated with radiation.
- You are generally able to care for yourself (ECOG score 0-3) and expected to live at least 3 more months.
- Your blood counts, liver, kidney, and heart function are within acceptable limits.
- You are not pregnant or breastfeeding, and have not had other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
This study tests a combination of targeted radiation (SBRT) and immunotherapy for people with esophageal cancer that has spread to a few spots in the body. The goal is to see if this approach helps control the cancer and improves your well-being.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
Hear when a new Recurrent or Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.